Annual Report to the Nation: Patient economic burden of cancer care over $21B

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Part two of the latest Annual Report to the Nation on the Status of Cancer found that in 2019, the national patient economic burden associated with cancer care was $21.09 billion, made up of patient out-of-pocket costs of $16.22 billion and patient time costs—the value of time that patients spend traveling to and from, waiting for, and receiving care—of $4.87 billion. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login